Published in:
Open Access 01-05-2008 | Article
Increasing overall physical activity and aerobic fitness is associated with improvements in metabolic risk: cohort analysis of the ProActive trial
Published in: Diabetologia | Issue 5/2008
Login to get accessAbstract
Aims/hypothesis
Our aim was to examine the association between change in physical activity energy expenditure (PAEE), total body movement (counts per day) and aerobic fitness (maximum oxygen consumption [\({\mathop {\text{V}}\limits^{\text{.}} }{\text{O}}_{{2\max }} \)]) over 1 year and metabolic risk among individuals with a family history of diabetes.
Methods
Three hundred and sixty-five offspring of people with type 2 diabetes underwent measurement of energy expenditure (PAEE measured using the flex heart rate method), total body movement (daily activity counts from accelerometry data), \({\mathop {\text{V}}\limits^{\text{.}} }{\text{O}}_{{2\max }} \) predicted from a submaximal graded treadmill exercise test and anthropometric and metabolic status at baseline and 1 year (n = 321) in the ProActive trial. Clustered metabolic risk was calculated by summing standardised values for waist circumference, fasting triacylglycerol, insulin and glucose, blood pressure and the inverse of HDL-cholesterol. Linear regression was used to quantify the association between changes in PAEE, total body movement and fitness and clustered metabolic risk at follow-up.
Results
Participants increased their activity by 0.01 units PAEE kJ kg−1 day−1 over 1 year. Total body movement increased by an average of 9,848 counts per day. Change in total body movement (β = −0.066, p = 0.004) and fitness (β = −0.056, p = 0.003) was associated with clustered metabolic risk at follow-up, independently of age, sex, smoking status, socioeconomic status and baseline metabolic score.
Conclusions/interpretation
Small increases in activity and fitness were associated with a reduction in clustered metabolic risk in this cohort of carefully characterised at-risk individuals. Further research to quantify the reduction in risk of type 2 diabetes associated with feasible changes in these variables should inform preventive interventions.
Clinical trial registration number: ISRCTN61323766.